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                                         Lovastatin is an antihyperlipidemic agent which has 
                                                                                                 
retention of lovastatin by development of a sustained release gastroretentive drug delivery 
                                                                                              
       : Floating microspheres were prepared by emulsion solvent diffusion technique, using 
various polymers and their blends. The in vitro performance was evaluated for drug-polymer 
                                                                                                    
                                                                                                
       :  The mean particle size of  microspheres was observed to be between 6.9 to 9.5 μm and 
the maximum particle size was around 50 μm. In vivo studies of the selected batches indicated 
lower level of serum cholesterol compared to the marketed tablet at the same dose but was not 
           
                                                                                            
dosage form of lovastatin can be successfully designed to yield controlled delivery with 
                             
        : Floating drug delivery system, In vitro drug release, Microsphere 
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Floating microspheres have been used as gastro- 
retentive system for : controlled drug delivery   
(1), separation of incompatible substances (2), 
improvement in dissolution and bioavailability of 
drugs (2), protection of compound from atmospheric 
decomposition (2), masking unfavorable odor and 
taste (3), sustained and prolonged release of the drug 
(4), and as a bioadhesive microsphere for intestinal 
(5) and nasal administration (6), radioopaque 
hydrogel microspheres for X-ray contrast  properties 
                                                      
organ in the body (e.g. lung) and even intracellular 
structures such as lysosomes and nucleus (8) 
and magnetically responsive microsphere system 
to localize the carriers and the entrap agents at 
                                                          
antihyperlipidemic agent inhibits the production 
of cholesterol by the liver. It lowers overall blood 
cholesterol as well as blood LDL cholesterol levels 
                                                 
a consequence of extensive hepatic extraction of 
lovastatin, the availability of the drug to the general 
circulation is low and variable (9). Moreover, 
conventional oral dosage form offers no control over 
                                                    
level. One of the approaches to improve the retention 
of oral dosage form in the stomach is to deliver 
lovastatin through hollow microspheres a non-
effervescent gastroretentive drug delivery system 
                                                       
and to improve bioavailability. Eudragit L 100 
and Eudragit S 100 are Poly(methacrylic acid, 
methyl methacrylate) 1 : 1 and  Poly(methacrylic 
acid, methyl methacrylate) 1 : 2 respectively and 
therefore their solubility characteristics  vary 
at different pH. Methocel K15 MP and ethocel 
standard 45 Pare cellulose derivatives with different 
aqueous solubility. Cyclodextrin has been used in 
the formulation to improve aqueous solubility of 
lovastatin. The present work is an effort to improve 
                                                        
microspheres for gastroretentive drug delivery. The 
                                                    
of lovastatin by using pure polymers and blends of 
polymers, characterization and evaluation of the 
                                                   
                                                        
microspheres.
                      
Lovastatin was obtained as a gift sample from Sun 
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Pharmaceutical Ind. Ltd (Mumbai, India). Eudragit 
S-100 and Eudragit L-100 were obtained from 
Röhm GmbH & Co.  KG. (Darmstadt, Germany). 
Methocel K15MP and Ethocel standard 45 P were 
obtained from (Dow Inc), (USA). All other reactants 
were analytical grades. 
The microspheres were prepared by using emulsion 
solvent diffusion method as described by Kawashima 
                                                      
and the polymer (Cyclodextrin was added as 
complexing agent in some batches) were dissolved 
or dispersed in a mixture of dichloromethane (25 
ml) and ethanol (25ml) at room temperature and 
dropped into 200 ml of 0.2% sodium lauryl sulphate 
(batch A1-A14) or to 200 ml of 1%w/v of PVA 
(batch B1-B7) with constant stirring at 500 rpm 
for 2 hrs employing a propeller type agitator. The 
                                                   
distilled water and dried at room temperature in a 
dessicator.
                       
A test solution was prepared (10μg/ml) and 
absorbance was measured at different wavelengths 
from 180 to 400 nm and maximum absorbance was 
determined at a wavelength of 239 nm.
                                                   
   
Stock solution of 100 μg/ml was prepared in 0.1N 
HCl and diluted to obtain concentrations of 0, 2, 4, 6, 
8 &10 μg/ml and analyzed spectrophotometrically 
at 239 nm against suitable blank. The results 
were plotted to obtain calibration equation 
(Absorbance=0.06452*Conc.) and correlation 
                     
                                  
             
Thoroughly dried microspheres were collected and 
weighed accurately. The percentage yield was then 
calculated using the formula:
% yield =
mass of microspheres obtained
      
total wt. of drug and polymer used
                       
A sample of 10 mg of microspheres was accurately 
weighed  and  dissolved  in  10  ml  of  0.1N  HCl.               
It was kept for 24 hrs to allow the dissolution of 
                                                    
of 10 μg/ml was prepared for all batches and was 
assayed spectrophotometrically at 239 nm against a 
suitable blank (10). All determinations were carried 
                                                    
then calculated using the formula:
% EE =
mass of incorporated drug in sampled 
microspheres
     
mass of drug used for preparation of 
sampled microspheres
                                         
The prepared microspheres were evaluated 
for particle size and size distribution by light    
microscopy using a calibrated eyepiece micrometer 
and a stage micrometer.
                                       
DSC Studies of drug loaded microspheres of different 
polymers were carried out by heating the samples 
from 40°C to 300°C at a rate of 10°C/minute using 
Differential Scanning Calorimeter.
                        
                                                        
                                                  
Micro balloons (10 mg) were dispersed in 0.1N 
                                                                                                    
yme
SLS
Dichloromethane (25 ml) and Ethanol (25 ml) were mixed
Lovastatin (drug) and Polymer (Cyclodextrin in some batches) 
were added dropwise with stirring
to 200 ml of 0.2 % SLS or to 200 ml of 1 % PVA
stirring for 2 hrs at 500
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bottom microspheres were separated after 2 hrs and 
dried overnight. The buoyancy was determined by 
                                                      
(11-14).
                       
In vitro release study of lovastatin from prepared 
microspheres was carried out using USP XXIII 
dissolution apparatus with paddle (Type 2) (in 
triplicates). The dissolution medium was 900 ml of 
0.1N HCl solution (37 °C) and 0.2% SLS solution 
(rpm=50). The weighed amounts of microspheres 
                                                    
                                                    
was withdrawn at every hour and replaced with 
an equal volume of fresh dissolution medium and 
             max 239 nm (9). The in vitro dissolution 
studies were carried out for a period of 4 hrs as it 
was speculated that any drug won’t stay for more 
than 4 hrs in gastric environment. The content of 
drug was calculated using the equation generated 
from standard curve (9).
                
In vivo studies were performed for the selected  best 
batch (A-4). Wistar rats were used for the estimation 
of serum cholesterol level using autoanalyzer 
(Erba Chem-5-plus V2, Erba Diagnostics Mannheim 
Gmbh, Germany). An oral dose of 25mg/kg of the 
body weight was administered and the cholesterol 
levels were measured in the test and formulation 
batches (n=3) Blood samples were collected by 
                                                    
serum was separated.  The study was performed 
taking lovastatin tablets as standard.  
For Blank (B): 20 μl distilled water + 1000 μl 
working reagent.
For Standard (S): 20 μl standard + 1000 μl working 
reagent.
For Test (T): 20 μl serum + 1000 μl working reagent.
The mixture incubated for 10 min at 37°C and 
                                                    
                                               (15, 
16).
               
Stability study was carried out on formulated 
microspheres after storing at 40°C and 75% relative 
humidity for one month and then drug content was 
analyzed.
                       
The percentage yield for the batches was found to be 
greater than 55% whereas three batches A-6 (87%), 
A-13 (79%) and A-14 (75%) had a yield higher 
than 75% which may be attributed to the presence 
of HPMC or Eudragit S-100 which yielded uniform 
dispersion in dichloromethane / ethanol mixture and   
precipitated in their absences.
                                                     
varied from 42.3 to 51.2%. The lower encapsulation 
                                                    
the presence of cyclodextrin as well as partitioning 
of the drug in aqueous and nonaqueous phases of 
the mixture.
The thermograms obtained after DSC are shown 
                                                         
                                                   
respectively. DSC indicated no physicochemical 
interaction or any other polymorphic change in the 
formulation (Table 1).
In vitro drug release study from the prepared 
microspheres was carried out for 4 hrs and the drug 
release was studied with respect to zero order and 
Higuchi matrix release parameters. Higher value of 
R2                                                      
                                                      
release from the microspheres followed Higuchi 
matrix release (Table 2) which was in accordance 
with the expected result that the drug is embedded in 
polymer matrix and the release of drug takes place 
by diffusion from this matrix gel network. The drug 
release from different batches A1 to A7, A8 to A14 
                                                  
Best four batches selected on the basis of their 
in vitro release were evaluated for their in vitro 
                                                                                  
                                                     
one hours (Table 3).
The mean particle size of microspheres was observed 
to be between 6.9 to 9.5 μm although the maximum 
particle size were around 50 μm in batch A-12 and 
A-14 as shown in table 4. It was observed that the 
                                                    
particle size whereas microspheres prepared with 
methocel K15MPand HPMC yielded larger particle 
size with polydisperse properties.
                                                        
controlling total cholesterol level in Wistar rats than 
the marketed standard (tablet). Based on student 
t-test value of  2.128 at p=0.05 the results are positive 
                            
The surface microscopy revealed a spherical surface 
for all formulations and a round cavity enclosed by 
           Peaks obtained at different temperatures for pure 
polymer, pure drug and formulated batches.
                              
1 Lovastatin 173
2                141.06
3 Ethocel 88.78
4 Methocel 144.6
5 A-12 (Methocel, Lovastatin) 144, 172
6 B-7 (Ethocel, Lovastatin) 88.78, 173.05                                                                    60
                 
 
                  
               
               
                                        
                                        
 
          Morphological characteristics of the best selected four batchesKumar et al / DARU 2011 19 (1) 57-64 61
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          In vitro drug release from batches (B1-B7) at different time intervals.
                                                   
R2      
                                    
A-1 100 - ES-100 (400) 0.9106 0.9744*
A-2 100 50 ES-100 (350) 0.9168 0.9846*
A-3 100 100 ES-100 (300) 0.9041 0.9640*
A-4 100 100
ES-100 (200)
EL-100 (100)
0.9206 0.9751*
A-5 100 100
ES-100 (150)
EL-100 (150)
0.9059 0.9597*
A-6 100 150 ES-100 (250) 0.7300 0.9437*
A-7 100 150
ES-100 (200)
EL-100 (50)
0.9677* 0.9673
A-8 100 - EL-100 (400) 0.8388 0.9870*
A-9 100 100 EL-100 (300) 0.8132 0.9661*
A-10 100 - HPMC (400) 0.9373 0.9684*
A-11 100 100 MC (300) 0.6700 0.9052*
A-12 100 - MC (400) 0.7289 0.9443*
A-13 100 100
MC (150)
HPMC (150)
0.8314 0.9852*
A-14 100 100 HPMC (400) 0.8597 0.9675*
                   
                                                   
R2      
                                    
B-1 100 - ES-100 (400) 0.8289 0.9778*
B-2 100 - MC (400) 0.8453 0.9818*
B-3 100 100 HPMC(300) 0.8159 0.9773*
B-4 100 - HPMC (400) 0.8151 0.9784*
B-5 100 - MC: HPMC (1:1) 0.7645 0.9596*
B-6 100 - EC(400) 0.8625 0,9736*
B-7 100 100 EC(300) 0.8557 0.9752*
                    
                                                                                                   2 value.
Time (min)
P
e
r
c
e
n
t
a
g
e
 
D
r
u
g
 
r
e
l
e
a
s
eKumar et al / DARU 2011 19 (1) 57-64 63
an outer shell composed of the drug and polymer. 
They appeared to be hollow presumably because of 
the rapid escape of volatile solvent from the polymer 
matrix. This hollow nature was also responsible for 
                                                      
                       
Stability study was carried out on formulated 
microspheres after storing at 40°C and 75% relative 
humidity for one month and no appreciable change 
were found in drug contents.
            
Lovastatin, a lipid lowering agent has oral 
bioavailability of only 5% and based on 
physicochemical nature of the drug it was expected 
that its oral bioavailability may be enhanced if the 
duration of stay in GIT is increased. To overcome 
the low water solubility, cyclodextrin was added as 
                   
                                         
                                
1 A-1 63.2±0.4 44.5±0.6 26.2±0.3
2 A-4 66.32±0.6 53.3±0.4 31.7±0.8
3 A-12 72.1±0.3 57.7±0.6 38.3±0.5
4 A-14 69.3±0.2 51.3±0.3 33.5±0.6
                                           
               
                            
1 A-1 9.3 73 15 8 4 -
2 A-4 6.9 87 9 2 2 -
3 A-12 9.25 69 22 4 3 1
4 A-14 9.5 75 14 3 7 1
                    
                                
                    
1 0.5 143.3 137.4 129.2 133.7 141.2 126.3
2 1 134.2 123.7 122.1 121.3 117.4 124.9
3 2 129.3 116.2 114.7 113.9 118.3 129.7
4 3 118.4 112.11 120.6 101.3 98.1 104.7
5 4 103.7 91.3 97.4 90.4 87.2 98.8
         In vitro buoyancy behavior of different batches at different time intervals.
         Particle size distribution of selected batches of microspheres containing lovastatin.
         Serum cholesterol level of the standard and the formulation with respect of time.
a complexing agent to some batches to increase the 
                                                        
The solubility and dissolution rates of lovastatin 
                                                  
inclusion complexation (17). Microspheres showed 
a particle size range between 3-61 μm. Batch no. 
A-4 (containing the ES-100 polymer and EL-100 
along with cyclodextrin) released 42.3% of drug. 
Drug entrapment in microspheres was higher for 
batch A-1 (51.2%) and A-4 (49.71%). Maximum 
buoyancy was shown by A-12 (methocel K15MP 
was used as the polymer) although batch A-4 showed 
buoyancy in more than 30% of microspheres even 
after 4 hrs. In vivo study for best selected batch (A-
4) was performed and lower level of cholesterol 
was obtained by using this formulation compared to 
the standard tablet but the results did not pass the 
student t-test and requires further investigation. 
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